TGLL: Triglyceride Lowering Study

• Sponsor: Jewish Hospital, Cincinnati, Ohio (Other)
• Overall Status: Unknown status
• CT.gov ID: NCT00934219
• Collaborator: GlaxoSmithKline (Industry)
• Enrollment: 25
• Location: 1
• Arms: 2
• Duration (Months): 41
• Patients Per Site Per Month: 0.6

Study Details

Study Description

Brief Summary

Lovaza is a special fish oil concentrate, that prescribed at 4 g a day to reduce certain fat (triglycerides) levels in blood.Our goal is to study how Lovaza at doses of 4, 8, and 12 grams per day will reduce fats in the blood of the patients with very high level of triglycerides. Our hypothesis is that patients with very high triglycerides will respond more with higher doses of Lovaza (8 g per day and then 12 g per day).

Condition or Disease	Intervention/Treatment	Phase
Hypertriglyceridemia	Drug: Omega-3-Acid Ethyl Esters	Phase 4

Detailed Description

Lovaza contains Omega-3 fatty acids, the family of poly- unsaturated fatty acids. Omega-3 fatty acids stimulate blood circulation, increases the breakdown of fibrin, and additionally has been shown to reduce blood pressure, cardiac events and mortality from congestive heart failure. There is strong scientific evidence that omega 3 fatty acids significantly reduce blood triglyceride levels while elevating high density lipoprotein cholesterol (HDL) levels. Fasting and non fasting hypertriglyceridemia have been associated with atherosclerosis, and coronary heart disease events, even in the absence of hypercholesterolemia. Severe hypertriglyceridemia (>2000 mg/dl) can also lead to acute hemorrhagic pancreatitis.

Currently, patients having very High TG are treated with Fibric acids (gemfibrozil, Tricor, Antara), and if hyperinsulinemic, with Glucophage. Lovaza (4g/day) has been shown to be effective and safe in lowering TG levels. There is no published data which indicates that Lovaza 8 or 12 g per day would have therapeutic effectiveness in further normalizing triglycerides in subjects on maximized triglyceride lowering and Lovaza 4 g per day. We hypothesize, based on our clinical experience that increasing Lovaza to 8 and then (if necessary) to 12 g/day would safely optimize triglycerides in subjects with primary hypertriglyceridemia who failed to normalize their triglycerides on optimal therapy including Lovaza 4 g/day.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 25 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza.
• Study Start Date: Jul 1, 2009
• Anticipated Primary Completion Date: Jul 1, 2012
• Anticipated Study Completion Date: Dec 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: High dose Lovaza Lovaza 4 g twice a day, if not effective then 4 g 3 times a day	Drug: Omega-3-Acid Ethyl Esters; LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).; Other Names: LOVAZA
Active Comparator: Standard Dose 2 g twice a day	Drug: Omega-3-Acid Ethyl Esters; LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).; Other Names: LOVAZA

Outcome Measures

Primary Outcome Measures

1. triglycerides level [7 months]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Primary hypertriglyceridemia with fasting TG levels >1000 mg/dl, and persistence of TG levels > 500 mg/dl despite maximal TG lowering therapy for 1 month, including Lovaza 4 g/day, fibric acids, and, where indicated, Glucophage for treatment of hyperinsulinemia.

2. Patients with mild to moderately impaired renal function should be initiated on TRICOR 48 mg and patients with severe renal impairment should not be given TRICOR.

3. Absence of exclusionary criteria (see below).

Exclusion Criteria:

1. Patients with known allergy to fish

2. Hypertriglyceridemia secondary to alcoholism, exogenous estrogens, nephrotic syndrome, hemochromatosis, glycogen storage disease, uncontrolled diabetes, exogenous corticosteroids, Cushing's syndrome, uremia).

3. Bleeding gastric or duodenal ulcers, active inflammatory bowel disease.

4. Pregnancy

5. Dementia

6. Patients with bleeding diatheses

7. Patients who are taking concomitant anticoagulants and other medications that affect bleeding time (e.g., warfarin, aspirin)

8. Patients with significantly abnormal transaminases (above 3x of upper normal limit)or any history of liver disease

9. Patients with conditions affecting the skin (e.g. malignancy, vasculitides) that may confound the skin exam.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Jewish Hospital Cholesterol Center	Cincinnati	Ohio	United States	45229

Sponsors and Collaborators

• Jewish Hospital, Cincinnati, Ohio
• GlaxoSmithKline

Investigators

• Principal Investigator: Charles Glueck, MD, JEWISH HOSPITAL CHOLESTEROL CENTER

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• Free Triglycerides lowering study

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00934219
• Other Study ID Numbers: TgLL8506
• First Posted: Jul 8, 2009
• Last Update Posted: Jul 8, 2009
• Last Verified: Jun 1, 2009

• Keywords provided by , ,: hypertriglyceridemia; triglycerides; familial hypertriglyceridemia
• Additional relevant MeSH terms: Hypertriglyceridemia

Study Results

No Results Posted as of Jul 8, 2009